<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cardiovasc Disord</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cardiovasc Disord</journal-id><journal-title-group><journal-title>BMC Cardiovascular Disorders</journal-title></journal-title-group><issn pub-type="epub">1471-2261</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28893175</article-id><article-id pub-id-type="pmc">5594538</article-id><article-id pub-id-type="publisher-id">673</article-id><article-id pub-id-type="doi">10.1186/s12872-017-0673-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Chronic kidney disease and diabetes associated with long-term outcomes in patients receiving percutaneous coronary intervention</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Mao-Jen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jung</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chun-Yu</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Chia-Chen</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0069-4183</contrib-id><name><surname>Wu</surname><given-names>Han-Ping</given-names></name><address><phone>+886-3-3281200</phone><email>arthur1226@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0572 899X</institution-id><institution-id institution-id-type="GRID">grid.414692.c</institution-id><institution>Division of Cardiology, Department of Medicine, </institution><institution>Taichung Tzu Chi Hospital, The Buddhist Tzu Chi Medical foundation, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0622 7222</institution-id><institution-id institution-id-type="GRID">grid.411824.a</institution-id><institution>Department of Medicine, </institution><institution>School of Medicine, Tzu Chi University, </institution></institution-wrap>Hualien, Taiwan </aff><aff id="Aff3"><label>3</label>Division of Pediatric General Medicine, Department of Pediatrics, Chang Gung Memorial Hospital at Linko, No. 5, Fu-Hsin Street, Kweishan, Taoyuan Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.145695.a</institution-id><institution>College of Medicine, Chang Gung University, </institution></institution-wrap>Taoyuan, Taiwan </aff><aff id="Aff5"><label>5</label>Department of Pediatric Emergency Medicine, Changhua Christian Children&#x02019;s Hospital, Changhua, Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>School of Medicine, Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 2041</institution-id><institution-id institution-id-type="GRID">grid.411641.7</institution-id><institution>Department of Public Health, </institution><institution>Chung Shan Medical University, </institution></institution-wrap>Taichung, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>242</elocation-id><history><date date-type="received"><day>27</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The effect of diabetes mellitus (DM) and chronic kidney disease (CKD) on long-term outcomes in patients receiving percutaneous coronary intervention (PCI) is unclear.</p></sec><sec><title>Methods</title><p id="Par2">A total of 1394 patients who underwent PCI were prospectively enrolled and divided into 4 groups according to the presence or absence of DM or CKD. Baseline characteristics, risk factors, medications, and angiographic findings were compared. Determinants of long-term outcomes in patients undergoing PCI were analyzed.</p></sec><sec><title>Results</title><p id="Par3">Patients with DM and CKD had the highest all-cause mortality and cardiovascular mortality (both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) but there were no differences existed in myocardial infarction (MI) or repeated PCI among the 4 groups (<italic>P</italic>&#x000a0;=&#x000a0;0.19, <italic>P</italic>&#x000a0;=&#x000a0;0.87, respectively). Patients with DM and CKD had the lowest even-free rate of all-cause mortality, cardiovascular mortality, MI, and repeated PCI (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, and <italic>P</italic>&#x000a0;=&#x000a0;0.002, respectively). In the Cox proportional hazard model, patients with both DM and CKD had the highest risk of all-cause mortality (HR: 3.25, 95% CI: 1.85&#x02013;5.59), cardiovascular mortality (HR: 3.58, 95% CI: 1.97&#x02013;6.49), MI (HR: 2.43, 95% CI: 1.23&#x02013;4.08), and repeated PCI (HR: 1.79, 95% CI: 1.33&#x02013;2.41). Patients with CKD alone had the second highest risk of all-cause mortality (HR: 2.04, 95% CI: 1.15&#x02013;3.63), cardiovascular mortality (HR: 2.13, 95% CI: 1.13&#x02013;4.01), and repeated PCI (HR: 1.47, 95% CI: 1.09&#x02013;1.97).</p></sec><sec><title>Conclusions</title><p id="Par4">DM and CKD had additive effect on adverse long-term outcomes in patients receiving PCI; CKD was a more significant adverse predictor than DM.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>PCI</kwd><kwd>Diabetes mellitus</kwd><kwd>Chronic kidney disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par33">Percutaneous coronary intervention (PCI) is common in patients with coronary artery disease(CAD). However, a lot of risk factors will affect the outcome after patients receiving PCI. Diabetes mellitus (DM) is a major risk factor that affects outcomes in CAD patients undergoing PCI [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Recently, chronic kidney disease (CKD) has emerged as a risk factor in terms of outcomes in patients undergoing PCI [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par34">The impact of DM and CKD on outcomes has been well studied in patients with acute coronary syndrome (ACS) undergoing PCI. Presence of CKD could affect long-term outcomes in patients with ST-elevation myocardial infarction (STEMI) managed by primary PCI and in-hospital mortality in patients with non-ST elevation myocardial infarction (non-STEMI) undergoing PCI [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. After undergoing PCI, diabetic patients suffered from ACS had worse short-term and mid-term outcomes than non-diabetic patients with ACS [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. As for patients with stable CAD who underwent PCI, diabetes was still an adverse predictor of mid-term outcomes.</p><p id="Par35">For ACS patients with both DM and CKD, the coexistence of DM and CKD appeared to have the higher risk of MACE than DM alone or CKD alone [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the combined effect of DM and CKD on long-term prognosis in patients undergoing PCI is still unclear. Our aim was to clarify and compare long-term outcomes among four groups of patients: patients with both DM and CKD, with only DM, with only CKD, and without CKD and DM. We further analyzed the adverse predictors of clinical outcomes among these 4 groups.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par36">A prospective cohort design using was conducted via medical records review from May 2007 to Dec 2014. The institutional review board and ethics committee approved the study protocol and monitoring for the study.</p><p id="Par37">We consecutively recruited patients aged 30 to 90&#x000a0;years who were to undergo PCI from the inpatient clinic at the Taichung Tzu Chi Hospital, Taiwan. According to isolated or coexistence of risk factors, the patients were divided into four groups: patients without DM or CKD, patients with DM alone, patients with CKD alone, and patients with both DM and CKD. Patients with a scheduled PCI and previous history of malignancy were excluded. Most patients obtained regular follow-up in the outpatient department (OPD). For some patients who were lost to follow-up, usually a phone call was used to contact the patients themselves or their families. A survey of cardiovascular mortality (CV mortality), all-cause mortality, myocardial infarction (MI), and repeated PCI procedures was completed at the end of the study.</p></sec><sec id="Sec4"><title>Data gathering and analysis</title><p id="Par38">Baseline characteristics including body habitus, biochemical data, angiographic findings from cardiac catheterization, exposed risk factors, and variant therapeutic strategies such as drug medications and invasive procedures (balloon angioplasty, bare metal stent deployment, or drug-eluting stent deployment) were all obtained for our study. Diabetes was defined as a fasting plasma glucose level of &#x0003e;126&#x000a0;mg/dL, a casual plasma glucose level of &#x0003e;200&#x000a0;mg/dL, or a hemoglobin A1c (HbA1c) level of &#x0003e;6.5% in this study [<xref ref-type="bibr" rid="CR14">14</xref>]. Estimated glomerular filtration rate (eGFR) and chronic kidney disease (CKD) stage were divided into 5 stages: stage l, eGFR &#x02265;90&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>; stage 2, eGFR of 60&#x02013;89&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>; stage 3, eGFR of 30&#x02013;59&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>; stage 4, eGFR of 15&#x02013;29&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>; and stage 5, eGFR of &#x0003c;15&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> or dialysis. CKD was defined as an eGFR of &#x0003c;60&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>, which was equal to or greater than CKD stage 3, in this study [<xref ref-type="bibr" rid="CR15">15</xref>]. Hypercholesterolemia was defined as a serum cholesterol level of &#x0003e;200&#x000a0;mg/dL or an LDL-C level of &#x0003e;100&#x000a0;mg/dLFor the angiographic and hemodynamic data, we measured the central aortic pressure (CAP) and left ventricular ejection fraction (LVEF). The CAP was obtained by using a pigtail catheter while performing a coronary angiography. Angiographic findings including number of diseased vessels and lesion locations were calculated, and lesion severity and complexity were evaluated via the Synergy between PCI with Taxus and cardiac surgery score (Syntax Score) [<xref ref-type="bibr" rid="CR16">16</xref>]. The left ventricular ejection was estimated through angiographic ventriculography or stress ventriculography.MI was defined as an MI attack after index PCI, accompanied by a 3-fold elevation in cardiac enzymes from the baseline value. General characteristics, major risk factors, angiographic findings, PCI strategies were analyzed, The primary end-points including all-cause death, cardiovascular death, myocardial infarction and repeated PCI were also compared among the 4 groups. The beginning of follow-up was the date of index PCI, and the duration of follow up was from the beginning through June 30, 2015 or if any of above primary end-points happened.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par40">The analysis was primarily used to assess differences among the 4 groups. Analysis of variance (ANOVA) was used for test continuous variables, and chi-square test was used to test categorical variables. Log-rank test and Kaplan&#x02013;Meier curves were used to compare survival differences. Cox proportional hazards model was used to test the effect of independent variables on hazards. <italic>P</italic> values of &#x0003c;0.05 were considered significant. All analyses were performed using the statistical package SPSS for Windows (Version 23.0 SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par41">During the whole study period, a total of 1394 patients who underwent a successful PCI procedure were enrolled. Among them, 509 patients in the control group had neither DM nor CKD, 254 patients had DM alone, 320 patients had CKD alone, and 311 patients had both DM and CKD. There were no differences in mean follow up time among the 4 groups (control group, 31.7&#x000a0;&#x000b1;&#x000a0;22.6&#x000a0;months; DM alone, 31.1&#x000a0;&#x000b1;&#x000a0;22.4&#x000a0;months; CKD alone, 23.8&#x000a0;&#x000b1;&#x000a0;19.7&#x000a0;months; and both DM and CKD, 23.0&#x000a0;&#x000b1;&#x000a0;19.2&#x000a0;months; <italic>P</italic>&#x000a0;=&#x000a0;0.08).</p><p id="Par42">General characteristics are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Patients with CKD alone and with both DM and CKD were much older than patients in the other groups (<italic>P&#x000a0;&#x0003c;</italic>&#x000a0;0.01). As for body habitus parameters, patients with CKD alone and patients with both DM and CKD had a lower body mass index(BMI), as compared with patients in the other 2 groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). As for the hemodynamic parameters, patients with both DM and CKD had the highest central systolic pressure (CSP) and lowest central diastolic pressure (CDP), as compared with patients in the other groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). As for baseline biochemistry, patients with both DM and CKD had the lowest cholesterol, low density lipoprotein-cholesterol(LDL-C) levels, and the poorest renal function (all <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01).<table-wrap id="Tab1"><label>Table 1</label><caption><p>General Characteristics of the Study Population</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="4">Study Groups</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th>Control (<italic>N</italic>&#x000a0;=&#x000a0;509)</th><th>DM alone (<italic>N</italic>&#x000a0;=&#x000a0;254)</th><th>CKD alone (<italic>N</italic>&#x000a0;=&#x000a0;320)</th><th>DM and CKD (<italic>N</italic>&#x000a0;=&#x000a0;311)</th></tr></thead><tbody><tr><td>Age (y)</td><td>58.1&#x000a0;&#x000b1;&#x000a0;10.8</td><td>59.6&#x000a0;&#x000b1;&#x000a0;10.3</td><td>72.2&#x000a0;&#x000b1;&#x000a0;10.1</td><td>68.6&#x000a0;&#x000b1;&#x000a0;10.3</td><td>&#x0003c;0.01</td></tr><tr><td>Weight (kg)</td><td>70.9&#x000a0;&#x000b1;&#x000a0;11.8</td><td>72.2&#x000a0;&#x000b1;&#x000a0;14.4</td><td>62.0&#x000a0;&#x000b1;&#x000a0;12.0</td><td>64.6&#x000a0;&#x000b1;&#x000a0;12.0</td><td>&#x0003c;0.01</td></tr><tr><td>Height (cm)</td><td>164.5&#x000a0;&#x000b1;&#x000a0;8.0</td><td>163.6&#x000a0;&#x000b1;&#x000a0;8.8</td><td>159.6&#x000a0;&#x000b1;&#x000a0;7.9</td><td>160.2&#x000a0;&#x000b1;&#x000a0;8.4</td><td>&#x0003c;0.01</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>26.2&#x000a0;&#x000b1;&#x000a0;3.6</td><td>26.9&#x000a0;&#x000b1;&#x000a0;4.3</td><td>24.3&#x000a0;&#x000b1;&#x000a0;3.9</td><td>25.1&#x000a0;&#x000b1;&#x000a0;3.8</td><td>&#x0003c;0.01</td></tr><tr><td>CSP</td><td>133.4&#x000a0;&#x000b1;&#x000a0;20.7</td><td>135.8&#x000a0;&#x000b1;&#x000a0;23.0</td><td>136.5&#x000a0;&#x000b1;&#x000a0;25.3</td><td>143.1&#x000a0;&#x000b1;&#x000a0;26.3</td><td>&#x0003c;0.01</td></tr><tr><td>CDP</td><td>76.0&#x000a0;&#x000b1;&#x000a0;12.3</td><td>73.8&#x000a0;&#x000b1;&#x000a0;13.1</td><td>70.7&#x000a0;&#x000b1;&#x000a0;13.1</td><td>70.3&#x000a0;&#x000b1;&#x000a0;13.2</td><td>&#x0003c;0.01</td></tr><tr><td>Cholesterol (mg/dL)</td><td>184.4&#x000a0;&#x000b1;&#x000a0;43.5</td><td>180.3&#x000a0;&#x000b1;&#x000a0;45.4</td><td>177.0&#x000a0;&#x000b1;&#x000a0;42.2</td><td>169.5&#x000a0;&#x000b1;&#x000a0;46.6</td><td>&#x0003c;0.01</td></tr><tr><td>HDL (mg/dL)</td><td>39.4&#x000a0;&#x000b1;&#x000a0;15.9</td><td>36.1&#x000a0;&#x000b1;&#x000a0;14.7</td><td>43.2&#x000a0;&#x000b1;&#x000a0;17.1</td><td>37.6&#x000a0;&#x000b1;&#x000a0;15.4</td><td>&#x0003c;0.01</td></tr><tr><td>TG (mg/dL)</td><td>160.0&#x000a0;&#x000b1;&#x000a0;105.0</td><td>171.5&#x000a0;&#x000b1;&#x000a0;117.1</td><td>134.9&#x000a0;&#x000b1;&#x000a0;94.1</td><td>161.2&#x000a0;&#x000b1;&#x000a0;110.1</td><td>&#x0003c;0.01</td></tr><tr><td>LDL (mg/dL)</td><td>113.0&#x000a0;&#x000b1;&#x000a0;39.7</td><td>109.6&#x000a0;&#x000b1;&#x000a0;36.7</td><td>106.9&#x000a0;&#x000b1;&#x000a0;36.3</td><td>99.7&#x000a0;&#x000b1;&#x000a0;38.2</td><td>&#x0003c;0.01</td></tr><tr><td>Serum creatinine (mg/dL)</td><td>0.9&#x000a0;&#x000b1;&#x000a0;0.2</td><td>1.0&#x000a0;&#x000b1;&#x000a0;0.3</td><td>2.2&#x000a0;&#x000b1;&#x000a0;2.4</td><td>3.2&#x000a0;&#x000b1;&#x000a0;3.3</td><td>&#x0003c;0.01</td></tr></tbody></table><table-wrap-foot><p>
<italic>DM alone</italic> diabetes alone, <italic>CKD alone</italic> chronic kidney disease alone, <italic>DM and CKD</italic> both DM and CKD, <italic>BMI</italic> body mass index, <italic>CSP</italic> central aortic systolic pressure, <italic>CDP</italic> central aortic diastolic pressure, <italic>HDL</italic> high-density lipoprotein cholesterol, <italic>LDL</italic> low-density lipoprotein cholesterol, <italic>TG</italic> triglyceride</p></table-wrap-foot></table-wrap>
</p><p id="Par43">Demographic data for the study population are shown on Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Female and hypertension preponderance were observed in patients with DM and CKD (both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01); they also had the highest prevalence of stroke history (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). However, patients with DM and CKD had the lowest prevalence of hypercholesterolemia and were the least likely to be current smokers (both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). In terms of medication after PCI, we found that patients with CKD alone had the lowest aspirin use (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01) and highest diuretic use (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). Patients with both DM and CKD had the lowest usage of angiotensin-converting enzyme inhibitors (ACEI) and statins (<italic>P</italic>&#x000a0;=&#x000a0;0.02 and <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, respectively).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Demographic Characteristics of the Study Population and Medication Use after the First PCI</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="4">Study Group</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th>Control (<italic>N</italic>&#x000a0;=&#x000a0;509)</th><th>DM Alone (<italic>N</italic>&#x000a0;=&#x000a0;254)</th><th>CKD Alone (<italic>N</italic>&#x000a0;=&#x000a0;320)</th><th>DM and CKD <italic>N</italic>&#x000a0;=&#x000a0;311)</th></tr></thead><tbody><tr><td>Gender</td><td/><td/><td/><td/><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>&#x02003;F</td><td>87 (17.1%)</td><td>60 (23.6%)</td><td>99 (30.9%)</td><td>120 (38.6%)</td><td rowspan="2"/></tr><tr><td>&#x02003;M</td><td>422 (82.9%)</td><td>194 (76.4%)</td><td>221 (69.1%)</td><td>191 (61.4%)</td></tr><tr><td>Hypertension</td><td/><td/><td/><td/><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>&#x02003;No</td><td>265 (52.1%)</td><td>103 (40.6%)</td><td>120 (37.5%)</td><td>91 (29.3%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>244 (47.9%)</td><td>151 (59.4%)</td><td>200 (62.5%)</td><td>220 (70.7%)</td></tr><tr><td>Hypercholesterolemia</td><td/><td/><td/><td/><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>&#x02003;No</td><td>189 (37.1%)</td><td>115 (45.3%)</td><td>139 (43.4%)</td><td>178 (57.2%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>320 (62.9%)</td><td>139 (54.7%)</td><td>181 (56.6%)</td><td>133 (42.8%)</td></tr><tr><td>Current smoker</td><td/><td/><td/><td/><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>&#x02003;No</td><td>269 (52.8%)</td><td>165 (65.0%)</td><td>202 (63.3%)</td><td>237 (76.2%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>240 (47.2%)</td><td>89 (35.0%)</td><td>118 (36.7%)</td><td>74 (23.8%)</td></tr><tr><td>MI</td><td/><td/><td/><td/><td char="." align="char">0.07</td></tr><tr><td>&#x02003;No</td><td>349 (68.5%)</td><td>170 (66.9%)</td><td>191 (59.7%)</td><td>202 (65.0%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>160 (31.5%)</td><td>84 (33.1%)</td><td>129 (40.3%)</td><td>109 (35.0%)</td></tr><tr><td>Stroke history</td><td/><td/><td/><td/><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>&#x02003;No</td><td>492 (96.7%)</td><td>242 (95.3%)</td><td>297 (92.8%)</td><td>283 (91.0%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>17 (3.3%)</td><td>12 (4.7%)</td><td>23 (7.2%)</td><td>28 (9.0%)</td></tr><tr><td>CABG history</td><td/><td/><td/><td/><td char="." align="char">0.06</td></tr><tr><td>&#x02003;No</td><td>509 (100.0%)</td><td>252 (99.2%)</td><td>317 (99.1%)</td><td>306 (98.4%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>0 (0.0%)</td><td>2 (0.8%)</td><td>3 (0.9%)</td><td>5 (1.6%)</td></tr><tr><td>Asprin</td><td/><td/><td/><td/><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>&#x02003;No</td><td>25 (4.9%)</td><td>15 (5.9%)</td><td>43 (13.4%)</td><td>37 (11.9%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>484 (95.1%)</td><td>239 (94.1%)</td><td>277 (86.6%)</td><td>274 (88.1%)</td></tr><tr><td>P2Y12 inhibitors</td><td/><td/><td/><td/><td char="." align="char">0.72</td></tr><tr><td>&#x02003;No</td><td>90 (17.7%)</td><td>43 (16.9%)</td><td>47 (14.7%)</td><td>50 (16.1%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>419 (82.3%)</td><td>211 (83.1%)</td><td>273 (85.3%)</td><td>261 (83.9%)</td></tr><tr><td>Diuretics</td><td/><td/><td/><td/><td char="." align="char">&#x0003c;0.01</td></tr><tr><td>&#x02003;No</td><td>435 (85.5%)</td><td>189 (74.4%)</td><td>234 (73.1%)</td><td>229 (73.6%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>74 (14.5%)</td><td>65 (25.6%)</td><td>86 (26.9%)</td><td>82 (26.4%)</td></tr><tr><td>Beta B</td><td/><td/><td/><td/><td char="." align="char">0.31</td></tr><tr><td>&#x02003;No</td><td>283 (55.6%)</td><td>130 (51.2%)</td><td>189 (59.1%)</td><td>175 (56.3%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>226 (44.4%)</td><td>124 (48.8%)</td><td>131 (40.9%)</td><td>136 (43.7%)</td></tr><tr><td>CCB</td><td/><td/><td/><td/><td char="." align="char">0.37</td></tr><tr><td>&#x02003;No</td><td>356 (69.9%)</td><td>164 (64.6%)</td><td>227 (70.9%)</td><td>212 (68.2%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>153 (30.1%)</td><td>90 (35.4%)</td><td>93 (29.1%)</td><td>99 (31.8%)</td></tr><tr><td>ACEI</td><td/><td/><td/><td/><td char="." align="char">0.02</td></tr><tr><td>&#x02003;No</td><td>396 (77.8%)</td><td>185 (72.8%)</td><td>244 (76.3%)</td><td>259 (83.3%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>113 (22.2%)</td><td>69 (27.2%)</td><td>76 (23.8%)</td><td>52 (16.7%)</td></tr><tr><td>ARB</td><td/><td/><td/><td/><td char="." align="char">0.18</td></tr><tr><td>&#x02003;No</td><td>401 (78.8%)</td><td>193 (76.0%)</td><td>246 (76.9%)</td><td>224 (72.0%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>108 (21.2%)</td><td>61 (24.0%)</td><td>74 (23.1%)</td><td>87 (28.0%)</td></tr><tr><td>Statin</td><td/><td/><td/><td/><td char="." align="char">&#x0003c; 0.01</td></tr><tr><td>&#x02003;No</td><td>281 (55.2%)</td><td>160 (63.0%)</td><td>222 (69.4%)</td><td>234 (75.2%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>228 (44.8%)</td><td>94 (37.0%)</td><td>98 (30.6%)</td><td>77 (24.8%)</td></tr><tr><td>Fibrate</td><td/><td/><td/><td/><td char="." align="char">0.05</td></tr><tr><td>&#x02003;No</td><td>472 (92.7%)</td><td>229 (90.2%)</td><td>306 (95.6%)</td><td>294 (94.5%)</td><td rowspan="2"/></tr><tr><td>&#x02003;Yes</td><td>37 (7.3%)</td><td>25 (9.8%)</td><td>14 (4.4%)</td><td>17 (5.5%)</td></tr></tbody></table><table-wrap-foot><p>
<italic>DM alone</italic> diabetes alone, <italic>CKD alone</italic> chronic kidney disease alone, <italic>DM and CKD</italic> both DM and CKD, <italic>previous MI</italic> history of previous myocardial infarction, <italic>CABG history</italic> history of coronary artery bypass graft, <italic>P2Y12 inhibitor</italic> P2Y12 receptor inhibitor of platelets, <italic>BB</italic> beta-blockers, <italic>CCB</italic> calcium channel blocker, <italic>ACEI</italic> angiotensin-converting enzyme inhibitor, <italic>ARB</italic> angiotensin receptor blocker</p></table-wrap-foot></table-wrap>
</p><p id="Par44">The angiographic findings and clinical outcomes are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. From the angiographic findings, double-vessel and triple-vessel disease were found more frequently in patients with both DM and CKD (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). There were no differences in invasive strategy among the 4 groups (<italic>P</italic>&#x000a0;=&#x000a0;0.34). As for adverse outcomes, patients with both DM and CKD had the highest all-cause mortality and cardiovascular mortality rate (both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01); however, there was no difference in MI or repeated PCI rate among the 4 groups (<italic>P</italic>&#x000a0;=&#x000a0;0.09 and <italic>P</italic>&#x000a0;=&#x000a0;0.32, respectively). Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> reveals the cumulative rate of freedom from MI, cardiovascular death, all-cause mortality, and repeated PCI among the 4 groups. Freedom from MI, all-cause mortality, CV death, and repeated PCI were lowest in the combined DM and CKD group (<italic>P</italic>&#x000a0;=&#x000a0;0.002, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, and <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, respectively).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Angiographic Findings and Outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="4">Study Group</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th>Control<break/>(N = 509)</th><th>DM alone<break/>(N = 254)</th><th>CKD alone (N = 320)</th><th>DM and CKD(N = 311)</th></tr></thead><tbody><tr><td>Follow-up time (months)</td><td>31.7 &#x000b1; 22.6</td><td>31.1 &#x000b1; 22.4</td><td>23.8 &#x000b1; 19.7</td><td>23.0 &#x000b1; 19.2</td><td>0.08</td></tr><tr><td>Number of diseased vessel</td><td/><td/><td/><td/><td>&#x0003c; 0.01*</td></tr><tr><td>&#x02003;Single-vessel disease</td><td>297 (58.4%)</td><td>120 (47.3%)</td><td>146 (45.6%)</td><td>106 (34.1%)</td><td/></tr><tr><td>&#x02003;Double-vessel disease</td><td>138 (27.1%)</td><td>75 (29.5%)</td><td>90 (28.1%)</td><td>112 (36.0%)</td><td/></tr><tr><td>&#x02003;Triple-vessel disease</td><td>74 (14.5%)</td><td>59 (23.2%)</td><td>84 (26.3%)</td><td>93 (29.9%)</td><td/></tr><tr><td>Mean treated vessels <sup>a</sup>
</td><td>1.2 &#x000b1; 0.4</td><td>1.3 &#x000b1; 0.5</td><td>1.3 &#x000b1; 0.5</td><td>1.3 &#x000b1; 0.5</td><td>&#x0003c; 0.01*</td></tr><tr><td>Mean treated lesions</td><td>1.4 &#x000b1; 0.7</td><td>1.5 &#x000b1; 0.8</td><td>1.5 &#x000b1; 0.8</td><td>1.6 &#x000b1; 0.9</td><td>0.07</td></tr><tr><td>Type of intervention</td><td/><td/><td/><td/><td>0.34</td></tr><tr><td>&#x02003;Balloon angioplasty (Yes)</td><td>163 (32.0%)</td><td>72 (28.4%)</td><td>109 (34.1%)</td><td>109 (35.1%)</td><td/></tr><tr><td>&#x02003;BMS deployment (Yes)</td><td>210 (41.3%)</td><td>87 (34.3%)</td><td>150 (46.9%)</td><td>130 (41.8%)</td><td/></tr><tr><td>&#x02003;DES deployment (Yes)</td><td>183 (36.0%)</td><td>120 (47.2%)</td><td>106 (33.1%)</td><td>116 (37.3%)</td><td/></tr><tr><td>Lesion location</td><td/><td/><td/><td/><td>0.31</td></tr><tr><td>&#x02003;LAD</td><td>358 (70.3%)</td><td>182 (71.7%)</td><td>236 (73.8%)</td><td>249 (80.0%)</td><td/></tr><tr><td>&#x02003;Lcx</td><td>223 (43.8%)</td><td>125 (49.2%)</td><td>160 (50.0%)</td><td>197 (63.3%)</td><td/></tr><tr><td>&#x02003;RCA</td><td>218 (42.8%)</td><td>125 (49.2%)</td><td>186 (58.1%)</td><td>182 (58.5%)</td><td/></tr><tr><td>SYNTAX score</td><td>9.8 &#x000b1; 7.2</td><td>11.8 &#x000b1; 8.3</td><td>11.0 &#x000b1; 7.7</td><td>11.2 &#x000b1; 8.1</td><td>0.12</td></tr><tr><td>LVEF</td><td>0.61 &#x000b1; 0.12</td><td>0.59 &#x000b1; 0.14</td><td>0.58 &#x000b1; 0.14</td><td>0.55 &#x000b1; 0.15</td><td>&#x0003c; 0.01*</td></tr><tr><td>MI</td><td/><td/><td/><td/><td>0.19</td></tr><tr><td>&#x02003;Yes</td><td>16 (3.1%)</td><td>13 (5.1%)</td><td>12 (3.8%)</td><td>19 (6.1%)</td><td/></tr><tr><td>&#x02003;No</td><td>493 (96.9%)</td><td>241 (94.9%)</td><td>308 (96.2%)</td><td>292 (93.9%)</td><td/></tr><tr><td>CV death</td><td/><td/><td/><td/><td>&#x0003c; 0.01*</td></tr><tr><td>&#x02003;Yes</td><td>16 (3.1%)</td><td>9 (3.5%)</td><td>27 (8.4%)</td><td>44 (14.2%)</td><td/></tr><tr><td>&#x02003;No</td><td>493 (96.9%)</td><td>245 (96.5%)</td><td>293 (91.6%)</td><td>267 (85.8%)</td><td/></tr><tr><td>All-cause death</td><td/><td/><td/><td/><td>&#x0003c; 0.01*</td></tr><tr><td>&#x02003;Yes</td><td>20 (3.9%)</td><td>15 (5.9%)</td><td>49 (15.3%)</td><td>57 (18.3%)</td><td/></tr><tr><td>&#x02003;No</td><td>489 (96.1%)</td><td>239 (94.1%)</td><td>271 (84.7%)</td><td>254 (81.7%)</td><td/></tr><tr><td>Re-PCI</td><td/><td/><td/><td/><td>0.87</td></tr><tr><td>&#x02003;Yes</td><td>127 (25.0%)</td><td>63 (24.8%)</td><td>72 (22.5%)</td><td>74 (23.8%)</td><td/></tr><tr><td>&#x02003;No</td><td>382 (75.1%)</td><td>191 (75.2%)</td><td>248 (77.5%)</td><td>237 (76.2%)</td><td/></tr></tbody></table><table-wrap-foot><p>
<italic>BMS</italic> bare metal stent, <italic>DES</italic> drug-eluting stent, <italic>LAD</italic> left anterior descending artery, <italic>Lcx</italic> left circumflex artery, <italic>RCA</italic> right coronary artery, <italic>SYNTAX score</italic> Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score, <italic>LVEF</italic> left ventricular ejection fraction, <italic>MI</italic> myocardial infarction, <italic>Re-PCI</italic> repeated percutaneous coronary intervention</p><p>
<sup>*</sup>: significant</p><p>
<sup>a</sup> : control vs DM alone: <italic>P</italic>=0.0059, control vs CKD alone: <italic>P</italic> = 0.0027, control vs DM and CKD: <italic>P</italic> = 0.0089, DM vs CKD: <italic>P</italic> = 0.7603, DM vs DM and CKD: <italic>P</italic> = 0.7070, CKD vs DM and CKD: <italic>P</italic> = 0.4160</p></table-wrap-foot></table-wrap>
<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold> Cumulative ratio of freedom from recurrent MI among the 4 groups (<italic>P</italic>&#x000a0;=&#x000a0;0.002). <bold>b</bold> Cumulative ratio of freedom from all death among the 4 groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). <bold>c</bold> Cumulative ratio of freedom from CV death among the 4 groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). <bold>d</bold> Cumulative ratio of freedom from Re-PCI among the 4 groups (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001)</p></caption><graphic xlink:href="12872_2017_673_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par45">An outcome analysis and outcome predictors from the Cox proportion hazard model for MI, all-cause mortality, CV death, and repeated PCI are listed in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. Patients with both DM and CKD carried the highest risk, as compared with the control group in terms of MI, CV death, all-cause mortality, and repeated PCI (hazard ratio [HR]: 2.43, 3.25, 3.58, and 1.79, respectively; all <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01). Based on the results from the Cox proportional hazard model, we found that previous MI and Syntax scores were predictors of MI (HR: 3.14 and 1.03, respectively), and statin use could reduce the risk of MI (HR: 0.46). Age, previous MI, stroke history, and Syntax score were predictors of all-cause death (HR: 1.04, 3.95, 1.97, and 1.03, respectively), beta blockers (BB) and statin use could reduce the risk (HR: 0.61 and 0.37, respectively). Previous MI, P2Y12 inhibitor use, and Syntax score were all predictors for CV death (HR: 4.29, 2.33, and 1.03, respectively); BB, ACEI, and statin use could reduce the risk of CV death (HR:0.53, 0.42, and 0.41, respectively). Finally, smoking and BB use were associated with repeated PCI (HR:1.57 and 1.40, respectively).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Significant Outcome Predictors in a Cox proportion hazard model for recurrent MI,All Death, CV Death, and Repeated PCI</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>RMI<sup>a</sup>
</th><th>All-cause death<sup>b</sup>
</th><th>CV-death<sup>c</sup>
</th><th>Repeated PCI<sup>d</sup>
</th></tr><tr><th>HR<sup>a</sup> (95% CI)</th><th>HR<sup>a</sup> (95% CI)</th><th>HR<sup>a</sup> (95% CI)</th><th>HR<sup>a</sup> (95% CI)</th></tr></thead><tbody><tr><td colspan="5">Group</td></tr><tr><td>&#x02003;Control</td><td>1.00 (Reference)</td><td>1.00 (Reference)</td><td>1.00 (Reference)</td><td>1.00 (Reference)</td></tr><tr><td>&#x02003;DM alone</td><td>1.43 (0.67&#x02013;3.06)</td><td>1.18 (0.59&#x02013;2.36)</td><td>0.91 (0.40&#x02013;2.09)</td><td>1.11 (0.82&#x02013;1.52)</td></tr><tr><td>&#x02003;CKD alone</td><td>1.47 (0.71&#x02013;3.08)</td><td>2.04 (1.15&#x02013;3.63)<sup>*</sup>
</td><td>2.13 (1.13&#x02013;4.01)<sup>*</sup>
</td><td>1.47 (1.09&#x02013;1.97)<sup>*</sup>
</td></tr><tr><td>&#x02003;DM and CKD</td><td>2.43 (1.23&#x02013;4.08)<sup>*</sup>
</td><td>3.25 (1.89&#x02013;5.59)<sup>**</sup>
</td><td>3.58 (1.97&#x02013;6.49)<sup>**</sup>
</td><td>1.79 (1.33&#x02013;2.41)<sup>**</sup>
</td></tr><tr><td>Age</td><td>-</td><td>1.04 (1.02&#x02013;1.05)<sup>**</sup>
</td><td align="center">-</td><td>-</td></tr><tr><td>Smoking</td><td>-</td><td align="center">-</td><td align="center">-</td><td>1.57 (1.25&#x02013;1.96)<sup>**</sup>
</td></tr><tr><td>Previous MI</td><td>3.14 (1.82&#x02013;5.40)<sup>**</sup>
</td><td>3.95 (2.72&#x02013;5.74)<sup>**</sup>
</td><td>4.29 (2.71&#x02013;6.79)<sup>**</sup>
</td><td>-</td></tr><tr><td>Stroke</td><td>1.88 (0.75&#x02013;4.74)</td><td>1.97 (1.16&#x02013;3.36)<sup>*</sup>
</td><td>1.72 (0.91&#x02013;3.25)</td><td>-</td></tr><tr><td>Diuretics</td><td>-</td><td align="center">-</td><td>1.35 (0.85&#x02013;2.15)</td><td>-</td></tr><tr><td>DES</td><td>-</td><td align="center">-</td><td align="center">-</td><td>-</td></tr><tr><td>Asprin</td><td/><td align="center">-</td><td>1.33 (0.66&#x02013;2.69)</td><td>-</td></tr><tr><td>P2Y12 inh</td><td/><td align="center">-</td><td>2.33 (1.01&#x02013;5.39)<sup>*</sup>
</td><td>-</td></tr><tr><td>BB</td><td>-</td><td>0.61 (0.43&#x02013;0.88)<sup>**</sup>
</td><td>0.53 (0.34&#x02013;0.83)<sup>**</sup>
</td><td>1.40 (1.23&#x02013;1.74)<sup>**</sup>
</td></tr><tr><td>CCB</td><td>-</td><td align="center">-</td><td align="center">-</td><td>-</td></tr><tr><td>ACEI</td><td>-</td><td align="center">-</td><td>0.42 (0.25&#x02013;0.73)<sup>**</sup>
</td><td>-</td></tr><tr><td>ARB</td><td>-</td><td align="center">-</td><td align="center">-</td><td>-</td></tr><tr><td>Statin</td><td>0.46 (0.26&#x02013;0.84)<sup>*</sup>
</td><td>0.37 (0.23&#x02013;0.58)<sup>**</sup>
</td><td>0.41 (0.24&#x02013;0.69)<sup>**</sup>
</td><td>-</td></tr><tr><td>Syntax</td><td>1.03 (1.01&#x02013;1.06)<sup>*</sup>
</td><td>1.03 (1.01&#x02013;1.04)<sup>**</sup>
</td><td>1.03 (1.01&#x02013;1.05)<sup>**</sup>
</td><td>1.00 (0.98&#x02013;1.01)</td></tr></tbody></table><table-wrap-foot><p>
<italic>DM alone</italic> diabetes alone, <italic>CKD alone</italic> chronic kidney disease alone, estimated glomerular filtration rate&#x000a0;&#x0003c;&#x000a0;60&#x000a0;mL/min; <italic>Previous MI</italic> history of previous myocardial infarction, <italic>DES</italic> drug-eluting stent, <italic>P2Y12 inh</italic> P2Y12 receptor inhibitor of platelets, <italic>BB</italic> beta-blockers, <italic>CCB</italic> calcium channel blocker, <italic>ACEI</italic> angiotensin-converting enzyme inhibitor, <italic>ARB</italic> angiotensin receptor blocker, <italic>Syntax score</italic> Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score</p><p>
<sup>*</sup>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, <sup>**</sup>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p><p>
<sup>a</sup>RMI model: y&#x000a0;=&#x000a0;&#x003b2;dummyDH1&#x000a0;+&#x000a0;&#x003b2;dummyDH2&#x000a0;+&#x000a0;&#x003b2;dummyDH3&#x000a0;+&#x000a0;&#x003b2;MI&#x000a0;+&#x000a0;&#x003b2;stroke + &#x003b2;statin + &#x003b2;syntax</p><p>
<sup>b</sup>All-death model: y&#x000a0;=&#x000a0;&#x003b2;dummyDH1&#x000a0;+&#x000a0;&#x003b2;dummyDH2&#x000a0;+&#x000a0;&#x003b2;dummyDH3&#x000a0;+&#x000a0;&#x003b2;age + &#x003b2;CKD + &#x003b2;MI&#x000a0;+&#x000a0;&#x003b2;stroke + &#x003b2;betab + &#x003b2;statin + &#x003b2;syntax</p><p>
<sup>c</sup>CV-death model: y&#x000a0;=&#x000a0;&#x003b2;dummyDH1&#x000a0;+&#x000a0;&#x003b2;dummyDH2&#x000a0;+&#x000a0;&#x003b2;dummyDH3&#x000a0;+&#x000a0;&#x003b2;MI&#x000a0;+&#x000a0;&#x003b2;stroke + &#x003b2;diuretics + &#x003b2;betab + &#x003b2;ACEI + &#x003b2;statin + &#x003b2;syntax</p><p>
<sup>d</sup>Repeated PCI model: y&#x000a0;=&#x000a0;&#x003b2;dummyDH1&#x000a0;+&#x000a0;&#x003b2;dummyDH2&#x000a0;+&#x000a0;&#x003b2;dummyDH3&#x000a0;+&#x000a0;&#x003b2;MI&#x000a0;+&#x000a0;&#x003b2;smoking + &#x003b2;betab + &#x003b2;syntax</p></table-wrap-foot></table-wrap>
</p><p id="Par46">Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> lists the incidence of adverse outcomes according to the different CKD stages. We found that patients with advanced-stage CKD (stage 4 and 5) had higher cardiovascular mortality and all-cause mortality than those with early-stage CKD (both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). However, there was no difference in terms of recurrent MI or repeated PCI (<italic>P</italic>&#x000a0;=&#x000a0;0.06 and <italic>P</italic>&#x000a0;=&#x000a0;0.20, respectively).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Incidence of Adverse Outcomes with Different CKD Stages According to Estimated Glomerular Filtration Rate</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Outcome</th><th colspan="5">CKD Stage</th><th rowspan="2">
<italic>P</italic> value</th></tr><tr><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th></tr></thead><tbody><tr><td colspan="7">MI</td></tr><tr><td>&#x02003;Yes</td><td>99 (32.5%)</td><td>143 (31.8%)</td><td>147 (35.0%)</td><td>50 (45.9%)</td><td>43 (39.1%)</td><td char="." align="char">0.0552</td></tr><tr><td>&#x02003;No</td><td>206 (67.5%)</td><td>306 (68.2%)</td><td>273 (65.0%)</td><td>59 (54.1%)</td><td>67 (60.9%)</td><td/></tr><tr><td colspan="7">CV death</td></tr><tr><td>&#x02003;Yes</td><td>11 (3.6%)</td><td>14 (3.1%)</td><td>32 (7.6%)</td><td>21 (19.3%)</td><td>18 (16.4%)</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>&#x02003;No</td><td>294 (96.4%)</td><td>436 (96.9%)</td><td>388 (92.4%)</td><td>88 (80.7%)</td><td>92 (83.6%)</td><td/></tr><tr><td colspan="7">All-cause death</td></tr><tr><td>&#x02003;Yes</td><td>16 (5.3%)</td><td>19 (11.4%)</td><td>48 (11.4%)</td><td>32 (29.4%)</td><td>26 (23.6%)</td><td char="." align="char">&#x0003c;0.0001</td></tr><tr><td>&#x02003;No</td><td>289 (94.7%)</td><td>431 (95.8%)</td><td>372 (88.6%)</td><td>77 (70.6%)</td><td>84 (76.4%)</td><td/></tr><tr><td colspan="7">Re-PCI</td></tr><tr><td>&#x02003;Yes</td><td>66 (21.6%)</td><td>124 (27.6%)</td><td>100 (23.8%)</td><td>20 (18.4%)</td><td>26 (23.6%)</td><td char="." align="char">0.2029</td></tr><tr><td>&#x02003;No</td><td>239 (78.4%)</td><td>326 (72.4%)</td><td>320 (76.2%)</td><td>89 (81.6%)</td><td>84 (76.4%)</td><td/></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par47">In patients with CAD undergoing PCI, we found that the highest rate of all-cause mortality, CV mortality, myocardial infarction, and repeated PCI occurred in patients with both DM and CKD, as compared with patients without DM and CKD, patients with DM alone, and patients with CKD alone. Patients with CKD alone had the second highest risk of all-cause mortality, cardiovascular mortality, and repeated PCI. As for the outcome analysis, we found that smoking and BB use was associated with repeated PCI procedures. Previous MI and Syntax scores were predictors of MI, and statin use could reduce the risk of MI. Age, previous MI, stroke history, and Syntax score were predictors of all-cause death, and BB and statin use could reduce the risk. Previous MI, P2Y12 inhibitor use, and Syntax score were all predictors of CV death, and BB, ACEI, and statin use could reduce the risk of CV death.</p><p id="Par48">In our study, patients with CKD alone, along with patients with both DM and CKD, were older and had a lower BMI; this is compatible with a previous study [<xref ref-type="bibr" rid="CR17">17</xref>]. Patients with both DM and CKD had a more elevated serum creatinine level than patients with CKD alone (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), implying that DM had an adverse impact on renal function in CKD patients. Secondarily, patients with both DM and CKD had the highest CSP and lowest CDP, thus they had the most elevated central pulse pressure (CPP). Elevated CPP is strongly associated with adverse cardiovascular outcomes in patients with hypertension patients and in patients after undergoing a PCI procedure in a previous study [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Elevated CPP in patients with DM and CKD may reflect that they had the most advanced arterial stiffness among the 4 groups.</p><p id="Par49">Patients with both DM and CKD had a higher prevalence rate of hypertension than patients with isolated DM or isolated CKD (both <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05), suggesting that DM and CKD had an additive effect on the acceleration of hypertension. In contrast, compared with patients with DM alone or CKD alone, patients with both DM and CKD used statins less frequently as they had the lowest serum cholesterol and LDL-C levels. Similarly, ACEI usage was also the least since patients with both DM and CKD had the poorest renal function and concern of increased hazard of hyperkalemia. When a patient has an LDL of &#x0003c;70&#x000a0;mg/dL, statin use has been found to improve cardiovascular outcomes in CAD patients after ACS [<xref ref-type="bibr" rid="CR20">20</xref>]; however, whether statin under-usage led to the poorest outcome in patients with both DM and CKD in this study remains to be clarified.</p><p id="Par50">Given for lesion location, intervention type such as balloon angioplasty, bare metal stent deployment, or drug-eluting stent deployment, there were no difference. However, patients with both DM and CKD had the highest prevalence of double-vessel disease and triple-vessel disease; they also had the lowest LVEF. Compared with patients with DM alone, patients with both DM and CKD had a significantly higher risk of developing multi-vessel disease (<italic>P</italic>&#x000a0;=&#x000a0;0.006); when compared with patients with CKD alone, patients with both DM and CKD also had a significantly higher risk of developing multi-vessel disease (<italic>P</italic>&#x000a0;=&#x000a0;0.01). Combined DM and CKD seemed to have an additive effect on the progression of atherosclerosis and development of multi-vessel disease than patients with isolated DM or isolated CKD. This is in contrast to a previous study that they observed patients with both DM and hypertension did not have a significant risk of developing multi-vessel disease, as compared with patients with DM alone [<xref ref-type="bibr" rid="CR21">21</xref>]. However, in terms of treated numbers of the vessels and lesions, no difference existed among patients with DM alone, CKD alone, or both DM and CKD (<italic>P</italic>&#x000a0;=&#x000a0;NS); thus, dominance of multi-vessel disease and poor left ventricular function in patients with DM and CKD may affect long-term outcomes in the present study. Beyond conventional risk factors for the development of CAD, other important prognostic indicators to assess in CAD patients include LVEF and number of diseased vessels [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par51">In our study, patients with DM and CKD had the highest rate of all-cause mortality and CV mortality. This may be due to patients with both DM and CKD had a higher rate of multi-vessel disease, along with a poorer LVEF, less statin use, and less ACEI use. On the contrary, while comparing patients with DM alone and CKD alone, patients with CKD alone had an increased rate of all-cause mortality and CV mortality than patients with DM alone (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 and <italic>P</italic>&#x000a0;=&#x000a0;0.02, respectively). However, there were no significant differences between the 2 groups regarding the number of diseased vessels, lesion complexity, LVEF, and medications. In this study, patients with CKD seemed had a poorer outcome than patient with DM. As been stated, a combination of insulin resistance and endothelial dysfunction leads to the progression of atherosclerosis in patients with DM and patients with CKD [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]; a larger scale clinical trial is necessitated to determine whether patients with CKD have more advanced insulin resistance and endovascular dysfunction than patients with DM.</p><p id="Par53">In conclusion, we found that patients with DM and CKD had the highest mortality after PCI than isolated DM or isolated CKD.; DM and CKD had an additive effect on long-term risks. In terms of adverse outcomes, patients with CKD seemed more hazardous than patients with DM.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par54">DM and CKD had additive effect on adverse long-term outcomes in patients with.</p><p id="Par55">CAD after receiving PCI. In patients receiving PCI, CKD was a more hazardous outcome predictor than DM.</p><sec id="Sec9"><title>Study limitations</title><p id="Par56">First, were did not fully evaluated the intensity of medication, such as tight blood glucose control or blood pressure control. Second, data entry bias may exist; functional evaluations of the atherosclerotic lesions such as fraction flow reserve (FFR) measurement, were not used that may have had an impact on the decision of index PCI enrollment; it has been reported that DM and CKD were independent predictors for FFR measurement. Besides, positive findings of FFR were lower in patients with CKD whereas index of microcirculatory resistance (IMR) was higher [<xref ref-type="bibr" rid="CR25">25</xref>].Third, since the number of patients in the DM alone group was fewer than that of the other groups, that may have affected the power of this study. Fourth, since DES implantation had a lower adverse cardiac events rate in patients with diabetes or CKD than BMS implantation, patient selection bias may exist in this study.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACEI</term><def><p id="Par5">Angiotensin-converting enzyme inhibitor</p></def></def-item><def-item><term>ARB</term><def><p id="Par6">Angiotensin receptor blocker.</p></def></def-item><def-item><term>BB</term><def><p id="Par7">Beta-blockers</p></def></def-item><def-item><term>BMI</term><def><p id="Par8">Body mass index</p></def></def-item><def-item><term>BMS</term><def><p id="Par9">Bare-metal stent</p></def></def-item><def-item><term>CABG</term><def><p id="Par10">Coronary artery bypass graft</p></def></def-item><def-item><term>CAD</term><def><p id="Par11">Coronary artery disease</p></def></def-item><def-item><term>CAP</term><def><p id="Par12">Central aortic pressure</p></def></def-item><def-item><term>CCB</term><def><p id="Par13">Calcium channel blockers</p></def></def-item><def-item><term>CDP</term><def><p id="Par14">Central aortic diastolic pressure</p></def></def-item><def-item><term>CKD</term><def><p id="Par15">Chronic kidney disease</p></def></def-item><def-item><term>CSP</term><def><p id="Par16">Central aortic systolic pressure</p></def></def-item><def-item><term>CV Mortality</term><def><p id="Par17">cardiovascular mortality</p></def></def-item><def-item><term>DES</term><def><p id="Par18">Drug-eluting stent</p></def></def-item><def-item><term>eGFR</term><def><p id="Par19">Estimated glomerular filtration rate</p></def></def-item><def-item><term>FFR</term><def><p id="Par20">Fraction flow reserve</p></def></def-item><def-item><term>HbA1c</term><def><p id="Par21">Hemoglobin A1C</p></def></def-item><def-item><term>HDL-C</term><def><p id="Par22">High-density lipoprotein-cholesterol</p></def></def-item><def-item><term>LAD</term><def><p id="Par23">Left anterior descending artery</p></def></def-item><def-item><term>Lcx</term><def><p id="Par24">Left circumflex artery</p></def></def-item><def-item><term>LDL-C</term><def><p id="Par25">Low-density lipoprotein- cholesterol</p></def></def-item><def-item><term>LVEF</term><def><p id="Par26">Left ventricular ejection fraction</p></def></def-item><def-item><term>MI</term><def><p id="Par27">Myocardial infarction</p></def></def-item><def-item><term>OPD</term><def><p id="Par28">Outpatient department</p></def></def-item><def-item><term>PCI</term><def><p id="Par29">Percutaneous coronary intervention</p></def></def-item><def-item><term>RCA</term><def><p id="Par30">Right coronary artery</p></def></def-item><def-item><term>SYNTAX score</term><def><p id="Par31">Synergy between percutaneous coronary intervention with taxus and cardiac surgery score</p></def></def-item><def-item><term>TG</term><def><p id="Par32">Triglyceride</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>None.</p><sec id="FPar1"><title>Funding</title><p id="Par57">This study was supported by a grant from the Department of Research, Taichung Tzu Chi Hospital, Taiwan.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par58">The data that support the findings of this study are available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MJL and HPW conceived and designed the study. MJL collected the study data. JL and CYC analyzed and interpreted the data. CCH performed the statistical analysis. MJ L drafted the manuscript, and HPW revised the manuscript. All authors had read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par59">The study protocol was approved by the Institution Review Board and ethics committee of Taichung Tzu Chi Hospital, Taiwan (REC104&#x02013;19) and written inform consents were obtained from all participants..</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par60">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par61">The authors declare that they have no competing interest.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par62">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>V</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Laskey</surname><given-names>WK</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the prevention of REStenosis with Tranilast and its outcomes (PRESTO) trial</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>476</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000109693.64957.20</pub-id><pub-id pub-id-type="pmid">14732749</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laskey</surname><given-names>WK</given-names></name><name><surname>Seizer</surname><given-names>F</given-names></name><name><surname>Viachos</surname><given-names>HA</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the national, heart, lung, and blood institute dynamic registry)</article-title><source>Am J Cardiol</source><year>2002</year><volume>90</volume><fpage>1062</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1016/S0002-9149(02)02770-4</pub-id><pub-id pub-id-type="pmid">12423704</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>PJ</given-names></name><name><surname>Berger</surname><given-names>PB</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Grines</surname><given-names>CL</given-names></name><name><surname>Sadeghi</surname><given-names>HM</given-names></name><collab>PRESTO Investigators</collab></person-group><article-title>Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><fpage>1786</fpage><lpage>1791</lpage><pub-id pub-id-type="pmid">15519008</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norhammar</surname><given-names>A</given-names></name><name><surname>Lagerqvist</surname><given-names>B</given-names></name><name><surname>Saleh</surname><given-names>N</given-names></name></person-group><article-title>Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry</article-title><source>EuroIntervention</source><year>2010</year><volume>5</volume><fpage>891</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.4244/EIJV5I8A152</pub-id><pub-id pub-id-type="pmid">20542773</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaya</surname><given-names>E</given-names></name><name><surname>Cuneo</surname><given-names>A</given-names></name><name><surname>Hochadel</surname><given-names>M</given-names></name><name><surname>J&#x000fc;nger</surname><given-names>C</given-names></name><name><surname>Stepper</surname><given-names>W</given-names></name><etal/></person-group><article-title>Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents</article-title><source>Clin Res Cardiol</source><year>2011</year><volume>100</volume><fpage>1103</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1007/s00392-011-0347-7</pub-id><pub-id pub-id-type="pmid">21912915</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ix</surname><given-names>JH</given-names></name><name><surname>Mercado</surname><given-names>N</given-names></name><name><surname>Schlipak</surname><given-names>MG</given-names></name><name><surname>Lemos</surname><given-names>PA</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS)</article-title><source>Am Heart J</source><year>2005</year><volume>149</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2004.10.010</pub-id><pub-id pub-id-type="pmid">15864241</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruberg</surname><given-names>L</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Mintz</surname><given-names>GS</given-names></name><name><surname>Kent</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure</article-title><source>Catheter Cardiovasc Interv</source><year>2002</year><volume>55</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/ccd.10103</pub-id><pub-id pub-id-type="pmid">11793497</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltzman</surname><given-names>AJ</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Claessen</surname><given-names>BE</given-names></name><name><surname>Narula</surname><given-names>A</given-names></name><name><surname>Leon-Reyes</surname><given-names>S</given-names></name><etal/></person-group><article-title>Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial</article-title><source>JACC Cardiovasc Interv</source><year>2011</year><volume>4</volume><fpage>1011</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2011.06.012</pub-id><pub-id pub-id-type="pmid">21939942</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>EB</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Fox</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention</article-title><source>JACC Cardiovasc Interv</source><year>2011</year><volume>4</volume><fpage>1002</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2011.05.022</pub-id><pub-id pub-id-type="pmid">21939940</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klempfner</surname><given-names>R</given-names></name><name><surname>Elis</surname><given-names>A</given-names></name><name><surname>Matezky</surname><given-names>S</given-names></name><name><surname>Keren</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><etal/></person-group><article-title>Temporal trends in management and outcome of diabetic and non-diabetic patients with acute coronary syndrome (ACS): residual risk of long-term mortality persists: insights from the ACS Israeli survey (ACSIS) 2000-2010</article-title><source>Int J Cardiol</source><year>2015</year><volume>179</volume><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2014.10.116</pub-id><pub-id pub-id-type="pmid">25466560</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>LO</given-names></name><name><surname>Maeng</surname><given-names>M</given-names></name><name><surname>Thayssen</surname><given-names>P</given-names></name><name><surname>Tilsted</surname><given-names>HH</given-names></name><name><surname>Terkelsen</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction</article-title><source>Am J Cardiol</source><year>2012</year><volume>109</volume><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2011.10.018</pub-id><pub-id pub-id-type="pmid">22152969</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>MB</given-names></name><name><surname>Cubbon</surname><given-names>RM</given-names></name><name><surname>Mercer</surname><given-names>B</given-names></name><name><surname>Wheatcroft</surname><given-names>AC</given-names></name><name><surname>Gherardi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Association of diabetes with increased all-cause mortality following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in the contemporary era</article-title><source>Diab Vasc Dis Res</source><year>2012</year><volume>9</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/1479164111427752</pub-id><pub-id pub-id-type="pmid">22067723</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Shiode</surname><given-names>N</given-names></name><name><surname>Shirota</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>Y</given-names></name><name><surname>Kitamura</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact of impaired renal function and diabetes on long-term prognosis in patients undergoing primary angioplasty for acute coronary syndrome</article-title><source>Intern Med</source><year>2008</year><volume>47</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.47.0932</pub-id><pub-id pub-id-type="pmid">18480574</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group><article-title>Diagnosis and classification of diabetes mellitus</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>suppl 1</issue><fpage>S67</fpage><lpage>S74</lpage><pub-id pub-id-type="doi">10.2337/dc13-S067</pub-id><pub-id pub-id-type="pmid">23264425</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Kidney Foundation</collab></person-group><article-title>K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease</article-title><source>Am J Kid Disney Dis</source><year>2003</year><volume>42</volume><fpage>S1</fpage><lpage>S201</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name><collab>SYNTAX Investigators</collab></person-group><article-title>Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0804626</pub-id><pub-id pub-id-type="pmid">19228612</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iimori</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>Y</given-names></name><name><surname>Okado</surname><given-names>T</given-names></name><name><surname>Naito</surname><given-names>S</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name><etal/></person-group><article-title>Baseline characteristics and prevalence of cardiovascular disease in newly visiting or referred chronic kidney disease patients to nephrology centers in Japan: a prospective cohort study</article-title><source>BMC Nephrol</source><year>2013</year><volume>14</volume><fpage>152</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-14-152</pub-id><pub-id pub-id-type="pmid">23865418</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Lacy</surname><given-names>PS</given-names></name><name><surname>Thom</surname><given-names>SM</given-names></name><name><surname>Cruickshank</surname><given-names>K</given-names></name><name><surname>Stanton</surname><given-names>A</given-names></name><collab>CAFE Investigators</collab></person-group><article-title>Anglo-Scandinavian Cardia outcomes trial investigators; CAFE steering committee and writing committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>1213</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.606962</pub-id><pub-id pub-id-type="pmid">16476843</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>HD</given-names></name><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>Wu</surname><given-names>HP</given-names></name></person-group><article-title>Prognostic significance of central pulse pressure for mortality in patients with coronary artery disease receiving repeated percutaneous coronary intervention</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><fpage>e3218</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000003218</pub-id><pub-id pub-id-type="pmid">27043689</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Blazing</surname><given-names>MA</given-names></name><name><surname>Giugliano</surname><given-names>RP</given-names></name><name><surname>MCCagg</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>JA</given-names></name><collab>IMPROVE-IT Investigators</collab></person-group><article-title>Ezetimibe added to Statin therapy after acute coronary syndromes</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>25</issue><fpage>2387</fpage><lpage>2397</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1410489</pub-id><pub-id pub-id-type="pmid">26039521</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>HD</given-names></name><name><surname>Wu</surname><given-names>HP</given-names></name></person-group><article-title>Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention</article-title><source>BMC Cardiovasc Disord</source><year>2017</year><volume>17</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s12872-016-0454-5</pub-id><pub-id pub-id-type="pmid">28056847</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valgimigli</surname><given-names>M</given-names></name><name><surname>Biscaglia</surname><given-names>S</given-names></name></person-group><article-title>Stable angina pectoris</article-title><source>Current atherosclero Rep</source><year>2014</year><volume>16</volume><fpage>422</fpage><pub-id pub-id-type="doi">10.1007/s11883-014-0422-4</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadi</surname><given-names>HA</given-names></name><name><surname>Suwaidi</surname><given-names>JA</given-names></name></person-group><article-title>Endothelial dysfunction in diabetes mellitus</article-title><source>Vasc Health Risk Manag</source><year>2007</year><volume>3</volume><fpage>853</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">18200806</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DT</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Irish</surname><given-names>AB</given-names></name><name><surname>Dogra</surname><given-names>GK</given-names></name></person-group><article-title>Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions</article-title><source>Nephrol Dial Transplant</source><year>2015</year><volume>0</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebaldi</surname><given-names>M</given-names></name><name><surname>Biscaqlia</surname><given-names>S</given-names></name><name><surname>Fineschi</surname><given-names>M</given-names></name><name><surname>Manari</surname><given-names>A</given-names></name><name><surname>Menozzi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fractional flow reserve evaluation and chronic kidney disease: analysis from a multicenter Italian registry (the FREAK study)</article-title><source>Catheter Cardiovasc Interv</source><year>2016</year><volume>88</volume><issue>4</issue><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1002/ccd.26364</pub-id><pub-id pub-id-type="pmid">26717890</pub-id></element-citation></ref></ref-list></back></article>